False Positive Activated Protein C Resistance Test due to Anti-Phospholipid Antibodies Is Corrected by Platelet Extract

• References

• 1 Halbmayer WM, Hauholer A, Schön K, Fischer M. Influence of lupus anticoagulant on a commercially available kit for APC-Resistance. Thromb Haemost 1994; 72: 645-646
• 2 Bokarewa MI, Blombäck M, Bremme K. APC-Resistance in the presence of phospholipid antibodies (PLa). Sixth International Symposium on Antiphospholipid Antibodies Leuven 09/1994; 14-17
• 3 Bokarewa MI, Blombäck M, Bremme K. Phospholipid antibodies (PLa) and resistance to activated protein C (APC-Resistance) in women with thrombophilia. Sixth International Symposium on Antiphospholipid Antibodies Leuven 09/1994; 14-17
• 4 Bokarewa MI, Blombäck M, Egberg N, Rosen S. A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coagul Librinolysis 1994; 5: 37-41
• 5 Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for Standardization of Lupus Anticoagulants. Thromb Haemost 1991; 65: 320-322
• 6 Dahlbäek B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a colactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
• 7 De Grool PG, Derksen RH W M. Protein G pathway. antiphospholipid antibodies and thrombosis Lupus 1994; 3: 229-233
• 8 Marciniak E, Romond EH. Impaired catalytic function of activated protein C: A new in vitro manifestation of lupus anticoagulant. Blood 1989; 74: 2426-2432
• 9 Borrell M, Sala N, de Caslellarnau C, Lopez S, Gari M, Fontcuberta J. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost 1992; 68: 268-272
• 10 Oosting JD, Derksen RH W M, Bobbink IW G, Hackeng TM, Bouma BN, De Grool PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism?. Blood 1993; 81: 2618-2625